Olema Pharmaceuticals, Inc. (OLMA) Financial Statements
Free cash flow over the same period: -$165.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OLMAOlema Pharmaceuticals, Inc.Follow OLMA — free
—
Price chart with a free account
- Market cap
- 560.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 51.1 | 82.3 | 86.1 | 124.5 | 157.7 | 190.2 | |
| Operating income | -71.5 | -107.0 | -105.0 | -142.3 | -178.7 | -221.1 | |
| Pre-tax income | -71.1 | -104.8 | -96.7 | -129.5 | -162.4 | -204.6 | |
| Income tax | — | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -71.1 | -104.8 | -96.7 | -129.5 | -162.5 | -204.6 | |
| Diluted EPS ($) | -1.80 | -2.62 | -2.14 | -2.20 | -1.87 | -1.97 | |
| Diluted shares (mn) | 39.5 | 40.0 | 45.2 | 58.7 | 87.0 | — |
USD millions · SEC XBRL
Olema Pharmaceuticals, Inc. — questions
- What is Olema Pharmaceuticals, Inc.'s net income?
- -$204.6M over the twelve months to 2026-06-30.
- What is Olema Pharmaceuticals, Inc.'s free cash flow?
- -$165.0M over the twelve months to 2026-06-30.
- What are Olema Pharmaceuticals, Inc.'s diluted earnings per share?
- $-1.97 over the twelve months to 2026-06-30.
Every figure on this page comes from Olema Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.